AMARIN CORP PLC\UK
About AMARIN CORP PLC\UK
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $213.6M
- Net income
- -$38.8M
- Total assets
- $670.8M
- Market cap
- $292.1M
- Gross margin
- 56.6%
- Operating margin
- -23.5%
- Net margin
- -18.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $213.6M
- Cost of revenue
- $92.8M
- Gross profit
- $120.9M
- Operating expenses
- $171.0M
- Operating income
- -$50.2M
- Income tax
- $2.8M
- Net income
- -$38.8M
- EPS (basic)
- $-0.09
- EPS (diluted)
- $-0.09
Balance sheet
- Total assets
- $670.8M
- Current assets
- $649.9M
- Total liabilities
- $211.5M
- Current liabilities
- $194.5M
- Shareholders’ equity
- $459.3M
Cash flow
- Operating cash flow
- $6.7M
- Investing cash flow
- $8.8M
- Financing cash flow
- -$2.0M
- Net cash flow
- $13.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $292.1M
- EPS (diluted)
- $-0.09
- Shares outstanding
- 20.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 1, 1993
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $38.8M in FY2025.
- Revenue declined 63% from FY2021 to FY2025.
- Gross margin of 56.6%, net margin -18.2%.
- Trading 30% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AMARIN CORP PLC\UK.
Write a review
News about AMARIN CORP PLC\UK
News & sentiment via Polygon.io
